1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Drugs In Development, 2022, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Cryptosporidiosis is an intestinal illness caused by a microscopic parasite called Cryptosporidium. Symptoms include watery diarrhea, dehydration, and lack of appetite, weight loss, fever, nausea and vomiting. Risk factors include contaminated water, animal handlers and parents of infected children.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Cryptosporidiosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Cryptosporidiosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 4 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Cryptosporidiosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptosporidiosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Cryptosporidiosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cryptosporidiosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cryptosporidiosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cryptosporidiosis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cryptosporidiosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cryptosporidiosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Cryptosporidiosis - Overview
- Cryptosporidiosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cryptosporidiosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cryptosporidiosis - Companies Involved in Therapeutics Development
- Cryptosporidiosis - Drug Profiles
- AV-0215W - Drug Profile
- Product Description
- Mechanism Of Action
- AV-0216W - Drug Profile
- Product Description
- Mechanism Of Action
- clofazimine - Drug Profile
- Product Description
- Mechanism Of Action
- D-121 - Drug Profile
- Product Description
- Mechanism Of Action
- DBAF-201 - Drug Profile
- Product Description
- Mechanism Of Action
- EDI-048 - Drug Profile
- Product Description
- Mechanism Of Action
- EPLAJ-1317 - Drug Profile
- Product Description
- Mechanism Of Action
- KDU-731 - Drug Profile
- Product Description
- Mechanism Of Action
- Polyclonal Antibodies - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Vector Vaccine for Protozoal Infection - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
- Product Description
- Mechanism Of Action
- Cryptosporidiosis - Dormant Projects
- Cryptosporidiosis - Discontinued Products
- Cryptosporidiosis - Product Development Milestones
- Featured News & Press Releases
- Mar 14, 2018: Calibr's repurposed drug to treat non-viral diarrhea enters into a clinical trial
- Feb 14, 2018: Novartis forms alliance to develop medicines for treating infectious diarrheal disease
- Nov 30, 2017: Novartis Institutes for BioMedical Research receives a grant of $1,542,000 from Bill & Melinda Gates Foundation
- May 31, 2017: Progress reported in global fight against diarrheal disease cryptosporidiosis
- May 01, 2017: Polyclonal antibodies used in the treatment of cryptosporidiosis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Cryptosporidiosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Cryptosporidiosis - Pipeline by AbbVie Inc, 2022
- Cryptosporidiosis - Pipeline by Aviex Technologies LLC, 2022
- Cryptosporidiosis - Pipeline by Epichem Pty Ltd, 2022
- Cryptosporidiosis - Pipeline by ImmuniMed Inc, 2022
- Cryptosporidiosis - Pipeline by ioGenetics Inc, 2022
- Cryptosporidiosis - Pipeline by Novartis AG, 2022
- Cryptosporidiosis - Pipeline by Oblita Therapeutics BVBA, 2022
- Cryptosporidiosis - Pipeline by PGTx Ltd, 2022
- Cryptosporidiosis - Dormant Projects, 2022
- Cryptosporidiosis - Discontinued Products, 2022
- Number of Products under Development for Cryptosporidiosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Aviex Technologies LLC
- Epichem Pty Ltd
- ImmuniMed Inc
- ioGenetics Inc
- Novartis AG
- Oblita Therapeutics BVBA
- PGTx Ltd
